Virginia-based wearable tech company Zansors has added to its growing collection of patents. Zansors was recently awarded a patent for a wearable patch to automatically monitor, screen, and/or report health conditions. Zansors’ next-generation intellectual property (IP) will allow health monitoring devices to detect sleeping or breathing disorders, according to the company.
“Zansors is developing and bringing to market, small wearable and easy-to-use devices that will represent the next generation in sleep apnea and lifestyle technologies. This latest patent represents an important step in implementing our devices into the daily life of our customers,” says Abhijit Dasgupta, PhD, inventor of the patent and co-founder and chief data science officer at Zansors, in a release.
This system for monitoring conditions can also be used to monitor and diagnose other medical conditions such as asthma, pneumonia, chronic obstructive pulmonary disease (COPD), congestive heart failure, arrhythmias, restless leg syndrome, seizures, falls, metabolic/nutritional levels, and sudden infant death syndrome (SIDS). Several wellness and fitness conditions can be monitored besides health conditions such as physical activity monitoring (ventilatory threshold, intensity and type, calorie expenditure, and sedentary vs. activity analysis), baby monitoring, from breaths.
This utility patent focuses on health monitoring via a wearable biosensor by employing algorithm and signal processing methods for physiological signals. Zansors was also previously issued a patent for specialized protecting adhesive to be used for wearable health sensor patches. These patents underpin the path to commercialization for Zansors’ R&D investments in wearable tech.
“Zansors is creating a future that allows remote detection of several health conditions that can be currently monitored only in a clinical setting. Linking subjective information from a mobile application with objective data using this system can provide a holistic picture of health, wellness and activity of the individual,” says Dasgupta. “Zansors’ wearable health tech is going to change how well you ‘know yourself.’”
Zansors says its new patent will lead to monitoring capability in the hands of consumers who can be empowered to monitor more of their health conditions on a continuous basis, instead of episodic screening in a clinical lab setting.
“The advancement in wearable biosensor technology can be further accelerated by innovations in signal processing for diagnostic purposes,” says Dale Lazar of DLA Piper, a global law firm. “The patent granted by the United States proves that Zansors is innovating effectively.” DLA Piper’s Reston, Virginia office supported patent prosecution.